Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-Line Dasatinib or Nilotinib Followed by Switch to Imatinib in CP-CML
NCT02709083Phase 2Terminated
- Sponsor
- Emory University
- Start
- Oct 2016
- Primary completion
- Jul 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib, nilotinib and imatinib in chronic myeloid leukemia (CML), sponsored by Emory University. Primary endpoint: Major Molecular Response at 12 months. Started Oct 2016; status: terminated.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02709083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709083.